Our study suggests several possible approaches to disrupt the function of ADAR1 in cancer cells: direct enzymatic inhibition of its adenosine deaminase activity and/or inactivation of non-enzymatic functions unique to the p150 isoform, such as direct PKR binding. This evidence concerns the gene ADA and cancer.